<!DOCTYPE html>
<html>
<head>
<meta name="viewport" content="width=device-width, initial-scale=1">
<link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css">
<link href="https://fonts.googleapis.com/css?family=Montserrat:600|Raleway|Karma" rel="stylesheet">
<link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.3.1/css/all.css" integrity="sha384-mzrmE5qonljUremFsqc01SB46JvROS7bZs3IO2EmfFsd15uHvIt+Y8vEf7N7fWAU" crossorigin="anonymous">

</head>
<style>
.gradient{width: 100%;height: 100vh;text-align: center;
background-image: radial-gradient(farthest-side at 55% 0%, #4FE9FB, #45CAF7, #389FF1,#2E80EC)}
.gradient2 {background: linear-gradient(to bottom, #f7fbfd, #fbfdff)}
.gradient3 {background: linear-gradient(to bottom, #f6f3ef, #fdfcfc)}
.lightBlue {color: #b6dcfa}
.superLightBlue {background-color: #f7fbfd}
.blue {background-color: #2E80EC}
.blueTxt {color: #2E80EC}
.sanB {font-family: 'Montserrat', sans-serif;}
.san {font-family: 'Raleway', sans-serif;}
.serif {font-family: 'Karma', serif;}

.pointer {
    cursor: pointer;
    height: 0.5em;
    width: 0.5em;
    background-color: #fc553d;
    border-radius: 50%;
    position: fixed;  
    z-index: 1;
    animation: blink 1.5s linear infinite;
    }
    @keyframes blink{
    0%{opacity: 0;}
    50%{opacity: 0.7}
    100%{opacity: 1;}
    }

.next {
    position: absolute; display: inline;
    left: 98vw; 
    background-color: transparent;
    color: transparent;
}


.noLine {text-decoration: none}

.menu {font-family: 'Montserrat', sans-serif;font-size: 2.5vmax;width: fit-content;
color:#b6dcfa;padding:0.5vmax;position: fixed;z-index: 3;display: none;
  top: 0.5vmax;left: 0.5vmax;text-align: center;cursor: pointer;
  }
.menuIcon :hover, .menuItem:hover {opacity: 0.7}

.hideItem {font-size: 2.5vmax;display: none;color: #0B3976;}
.menuItem {padding: 0.5vmax;background-color: #e1ded7;font-size: 1.8vmax;margin-top: 0.1vh;}
.menuItem a {text-decoration: none}

.block {margin: 3vh 0;position: relative;padding-top:5vh;}
.blockHolder  {margin: 0 3vw;border-radius: 1vw;padding: 1vmax}
.eyebrow {height: 1vh;margin: 1vh 1vw;width: 15%;
background: linear-gradient(to right,#45CAF7,#cbe6fb,#ece6df,#cfc1af)}
.topic {margin-left: 1vmax;font-size: 0;font-family: 'Raleway', sans-serif;}
.topic :first-child {color: #2E80EC;font-size: 2vmax;}
.topic :nth-child(2) {color:#b29c7f;font-size:2vmax}
.imgSec {padding: 5vh 2vw}
.headline {padding:2vmax 3vmax 0.5vmax 3vmax;font-family: 'Karma', serif;color:#0B3976;
font-size: 3vmax;line-height: 100%}
.text {color: #969696;font-family: 'Raleway', sans-serif;line-height: 120%;font-size: 2vmax;
        padding: 0.5vmax 3vmax}

.firstL {font-size: 4vmax;color: #2E80EC}
.ref {font-family: 'Karma', serif;font-size: 1vmax;color: #969696}
.hoverBlue li:hover {color: #2E80EC;}
.largeImg {max-height:80vh;overflow-y: scroll}
.largeImg :first-child {width: 90%}
.bText {color:#b29c7f;font-weight:700}

</style>

<!--home-->
<div id="Top" class="block" style="padding:0;margin:0;background:transparent"></div>
<div class="gradient">
    <div class="san w3-row" style="font-size:2vmax;color: white;padding-top:30vh">
        <span>'17-'18</span>
        <span style="border: 0.2vmin white solid;background:white;mix-blend-mode:screen">
            <span style="color:black;">UPDATE</span>
        </span>
    </div>
    <div class="sanB" style="font-size: 5vmax;color: white;text-align: center">
        <a href="#glines" class="noLine" onclick="unblur()">
        Heart Failure Rx</a></div>
    <div class="san lightBlue" style="font-size: 2.5vmax;">
        <a href="#glines" class="noLine"  onclick="unblur()">guidelines</a> | 
        <a href="#trial" class="noLine"  onclick="unblur()">trials</a>
    </div>
    <div style="padding-top:2vmax;font-size: 2vmax" class="san lightBlue">
    <a href="https://www.facebook.com/HeartRhythmBox" class="noLine" target="_blank">
        <i class="fab fa-facebook-square" style="font-size:2vmax;color:white"></i>
        HeartRhythmBox
    </a></div>
</div>

<!--menu-->
<div class="menu">
    <div class="w3-bar">
        <div class="w3-bar-block  menuIcon" onclick="showMenu()">
        <i class="fab fa-creative-commons-nd" style="text-shadow:rgba(203, 230, 251, 0.6) 1px 1px 10px"></i>
        </div></div>

    <!--onclick-->
    <div class="hideItem w3-bar w3-center">
    <div class="w3-bar-block"><i class="fas fa-chevron-circle-down" onclick="hideMenu()"></i></div>
    <div class="w3-bar-block menuItem" title="guidelines">
        <a href="#glines">G</a></div>
    <div class="w3-bar-block menuItem" title="trials">
        <a href="#trial">T</a></div>
    <div class="w3-bar-block menuItem" title="@HeartRhythmBox">
        <a href="https://www.facebook.com/HeartRhythmBox" class="noLine" target="_blank">
            <i class="fab fa-facebook-square"></i></a></div>
    <div class="w3-bar-block menuItem" title="to Top">
        <a href="#Top"><i class="fas fa-arrow-circle-up"></i></a>
    </div>
    </div>
    </div>
    
</div>

<!--start pointer-->
<div onclick="pointer()"><span class="pointer" style="display: none"></span> 
<!--guidelines- intro-->
<div id="glines" class="block">
    <div class="blockHolder gradient2">
    <div class="eyebrow"></div>
    <div class="topic">
        <span>Guidelines ></span>
        <span>> ACC & Nice</span>
    </div>
    <div class="imgSec w3-row w3-center w3-border-bottom">
        <div class="w3-col s6">
        <a href="https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000509" target="_blank">
            <img src="media/ACC/paper.png" style="width:100%"></a></div>
        <div class="w3-col s6 w3-leftbar">
        <a href="https://www.nice.org.uk/guidance/ng106" target="_blank">
            <img src="media/NICE/paper.png" style="width:100%"></a></div>
    </div>
    <div class="headline">
       ACC and NICE published their new guidelines last year and this year respectively.
    </div>
    <div class="text">
        Minor dissimiarlities do occur, of course.
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
    </div>
</div>

<!--guidelines- BNP-->
<div class="block">
    <div class="blockHolder gradient2">
    <div class="eyebrow"></div>
    <div class="topic">
        <span>Guidelines ></span>
        <span>> NT proBNP</span>
    </div>
    <div class="imgSec w3-row w3-center w3-border-bottom largeImg">
        <img src="media/NICE/Dx Algo.jpg">
    </div>
    <div class="headline">
       NICE said... NT proBNP has a greater
       sensitivity over a range of thresholds compared to BNP. 
    </div>
    <div class="text">
        Also, NT proBNP has a longer stability in blood samples and is not interfered by Sacubitril Valsartan 
        compared to BNP. NICE, therefore, recommended NT proBNP over BNP as a diagnostic and prognostic marker
        of heart failure. ACC, on the other hand, recommended either one.
        <div class="ref">
            <a href="https://www.nice.org.uk/guidance/ng106/evidence/full-guideline-pdf-6538850029">
            2018 NICE full guideline</a>
            <a href="https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000509">
            2017 ACC focused update</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
    </div>
</div>


<!--guidelines fundamental-->
<div class="block">
    <div class="blockHolder gradient2">
    <div class="eyebrow"></div>
    <div class="topic">
        <span>Guidelines ></span>
        <span>> Fundamental of HF Rx</span>
    </div>
    
    <ul class="sanB w3-center hoverBlue" style="font-size:2.5vmax;line-height:130%;margin-top: 2vmax;padding: 2vmax;
    list-style: none;color: #969696">
        <li><span class="firstL">I</span>NFORMATION & SUPPORT </li>
        <li><span class="firstL">S</span>ALT & <span class="firstL">F</span>LUID CONSUMPTION</li>
        <li><span class="firstL">A</span>LCOHOL & <span class="firstL">S</span>MOKING CESSATION</li>
        <li><span class="firstL">T</span>RAVELLING & <span class="firstL">D</span>RIVING</li>
        <li><span class="firstL">C</span>ONTRACEPTION </li>
        <li><span class="firstL">V</span>ACCINATIONS</li>
    </ul>
       
    <div class="ref w3-center">
        <a href="https://pathways.nice.org.uk/pathways/chronic-heart-failure#path=view%3A/pathways/chronic-heart-failure/managing-chronic-heart-failure.xml&content=view-index">
        NICE Pathways</a>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
    </div>
</div>


<!--guidelines- HFrEF first line-->
<div class="block">
    <div class="blockHolder gradient2">
    <div class="eyebrow"></div>
    <div class="topic">
        <span>Guidelines ></span>
        <span>> HFrEF</span>
    </div>
    <div class="imgSec w3-row w3-center w3-border-bottom largeImg">
        <img src="media/ACC/HFrEF algo.png">
    </div>
    <div class="headline">
        ACEI/ARB and Beta Blockers remain the first line treatment of HFrEF to reduce morbidity
        and mortality.
    </div>
    <div class="text">
        Diuretic is recommended to relieve the symptoms of congestion and fluid retention. 
        <div class="ref">
            <a href="https://www.nice.org.uk/guidance/ng106/evidence/full-guideline-pdf-6538850029">
            2018 NICE full guideline</a> and
            <a href="https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000509">
            2017 ACC focused update</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
    </div>
</div>

<!--guidelines- HFrEF ARNI-->
<div class="block">
    <div class="blockHolder gradient2">
    <div class="eyebrow"></div>
    <div class="topic">
        <span>Guidelines ></span>
        <span>> HFrEF -- ARNI</span>
    </div>
    <div class="imgSec w3-row w3-center w3-border-bottom">
        <img src="media/Paradigm.png" style="width:100%">
    </div>
    <div class="headline">
        In patients with HFrEF NYHA class II or III
        who tolerate an ACEI or ARB, replacement by an ARNI is
        recommended to further reduce morbidity and mortality.
    </div>
    <div class="text">
        In ARNI, an ARB is combined with an inhibitor of neprilysin, an enzyme that degrades 
        natriuretic peptides, bradykinin, adrenomedullin, and other vasoactive peptides. <br>
        Inhibition of neprilysin increases the levels of these substances, countering the 
        neurohormonal overactivation that contributes to vasoconstriction, sodium retention, 
        and maladaptive remodeling.
        <div class="ref">
            <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1409077">
            PARADIGM-HF</a> and
            <a href="https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000509">
            2017 ACC focused update</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
    </div>
</div>

<!--guidelines- HFrEF 2nd line-->
<div class="block">
    <div class="blockHolder gradient2">
    <div class="eyebrow"></div>
    <div class="topic">
        <span>Guidelines ></span>
        <span>> HFrEF -- second-line</span>
    </div>
    <div class="imgSec w3-row w3-center w3-border-bottom largeImg">
        <img src="media/ACC/HFrEF second line.png" style="width:50%">
    </div>
    <div class="headline">
        Recommendation for MRA and hydralazine/nitrates remained unchanged.
    </div>
    <div class="text">
        
        <div class="ref">
            <a href="https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000509">
            2017 ACC focused update</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
    </div>
</div>

<!--guidelines- HFrEF Ivabradine-->
<div class="block">
    <div class="blockHolder gradient2">
    <div class="eyebrow"></div>
    <div class="topic">
        <span>Guidelines ></span>
        <span>> HFrEF -- Ivabradine</span>
    </div>
    <div class="imgSec w3-row w3-center w3-border-bottom">
        <img src="media/SHIFT.jpg" style="width:100%">
    </div>
    <div class="headline">
        Recommended for the 1st time, as class IIa, in ACC.
    </div>
    <div class="text">
            Ivabradine can be beneficial to reduce HF hospitalization for patients
            with stable chronic HFrEF who are receiving GDEM, including a beta blocker at maximum
            tolerated dose, and who are in sinus rhythm with a heart rate of 70 bpm
            or greater at rest.<br>
            NICE recommended Ivabradine since 2012.
        <div class="ref">
            <a href="https://www.sciencedirect.com/science/article/pii/S0140673610611981?via%3Dihub">
            SHIFT</a> and
            <a href="https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000509">
            2017 ACC focused update</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
    </div>
</div>

<!--guidelines- HFrEF Device Therapy-->
<div class="block">
        <div class="blockHolder gradient2">
        <div class="eyebrow"></div>
        <div class="topic">
            <span>Guidelines ></span>
            <span>> HFrEF -- CIEDs</span>
        </div>
        <div class="w3-row" style="margin-top:2vh">
            <div class="w3-col s6 w3-mobile w3-padding w3-border-right">
                    <img src="media/NICE/NICE device.png" style="width: 100%">    
            </div>
            <div class="w3-col s6 w3-mobile">
                    <div class="headline">
                            Nothing new. Just added the end-of-life care planning.
                    </div>
                    <div class="text">
                    Before implantation, 
                    explain the function of the device and the circumstances in which 
                    deactivation might be offered, and 
                    discuss the consequence of deactivation.  
                    <br><br>
                    Provide the person and, if they wish, their family or carers
                     with written information covering the information discussed.   
                    <div class="ref">
                       <a href="https://www.nice.org.uk/guidance/ng106/chapter/Recommendations#interventional-procedures">
                        2018 NICE Guideline</a> 
                    </div></div>
            </div>
        </div>
        <div class="w3-btn next" onmouseover="blockNav(1)"></div>
        </div>
    </div>

<!--guidelines- HFpEF -->
<div class="block">
        <div class="blockHolder gradient2">
        <div class="eyebrow"></div>
        <div class="topic">
            <span>Guidelines ></span>
            <span>> HFpEF -- TOPCAT</span>
        </div>
        <div class="imgSec w3-row w3-center w3-border-bottom">
            <div class="w3-col s4 w3-padding">
                <img src="media/TOPCAT main.png" style="width:100%"> </div>
            <div class="w3-col s8 w3-border-left">
                <img src="media/TOPCAT post hoc.png" style="width:100%">
            </div>
        </div>
        <div class="headline">
            In addition to antihypertensives and diuretic, ACC recommended spironolactone
            as a class IIb for patients with HFpEF.
        </div>
        <div class="text">
                <span class="bText">"A positive re-look from a negative trial"</span><br>
                In TOPCAT trial, treatment with spironolactone in HFpEF did not significantly reduce
                primary outcome. A post-hoc analysis, however, showed significant regional variation and
                a greater benefits in patients from Americas than those from Russia and Georgia.
            <div class="ref">
                <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1313731">
                TOPCAT</a> and
                <a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.114.013255">
                TOPCAT post-hoc</a>
            </div>
        </div>
        <div class="w3-btn next" onmouseover="blockNav(1)"></div>
        </div>
    </div>

<!--guidelines- sum-->
<div class="block">
        <div class="blockHolder gradient2">
        <div class="eyebrow"></div>
        <div class="topic">
            <span>Guidelines ></span>
            <span>> Summary</span>
        </div>
        <div class="headline">
                A "NICE" summary on management of chronic heart failure
            </div>
        <div class="imgSec w3-row w3-center w3-border-top">
            <img src="media/NICE/NICE med algo.jpg" style="width:100%">
        </div>
        <div class="ref w3-center">
            <a href="https://www.nice.org.uk/guidance/ng106/evidence/full-guideline-pdf-6538850029">
                2018 NICE full guideline</a>
        </div>
       
        <div class="w3-btn next" onmouseover="blockNav(1)"></div>
        </div>
    </div>

<!--Trials-->

<!--CAMERA MRI-->
<div id="trial" class="blockHolder gradient3" style="margin-top: 6vh">
    <!--intro-->
    <div class="block" style="margin:0;padding: 0">
        <div class="eyebrow"></div>
        <div class="topic">
        <span>Trials ></span>
        <span>> CAMERA-MRI</span>
        </div>
        <div class="ref" style="margin-left: 1.2vmax">
            <a href="https://www.sciencedirect.com/science/article/pii/S073510971739349X?via%3Dihub" target="_blank">
                ref: CAMERA-MRI</a>
        </div>
        
        <div class="w3-row" style="margin-top:7vh">
            <div class="w3-col s6 w3-mobile w3-center">
                <a href="https://www.sciencedirect.com/science/article/pii/S073510971739349X?via%3Dihub" target="_blank">
                <img src="media/Camera/frontpage.png" style="width:100%"></a></div>
            <div class="w3-col s6 w3-mobile w3-center">
                <ul class="sanB w3-center hoverBlue" 
                style="font-size:2.5vmax;line-height:130%;list-style: none;color: #969696">
                    <li><span class="firstL">CAMERA-MRI</span></li>
                    <li>RCT, MULTICENTER</li>
                    <li>PERSISTENT AF</li>
                    <li>IDIOPATHIC CM</li>
                    <li>CATHETER ABLATION <span class="blueTxt">vs. </span>MEDICAL RATE CONTROL</li>
                    
                </ul>
            </div>
        </div>
     
        <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
    </div>

    <!--baseline char-->
    <div class="block" style="margin-top:10vh">
                      
        <div class="w3-row">
            <div class="w3-col l4 m4 s6 w3-mobile w3-padding">
                <img src="media/Camera/lesions.png" style="width:100%"></div>
            <div class="w3-col w3-mobile l8 m8 s6">
                <ul class="sanB hoverBlue w3-ul" style="font-size:2.5vmax;color: #969696">
                    <li>N=301, Age=61, LVEF=33%.</li>
                    <li>Catheter ablation = PVI + Box lesion.</li>
                    <li>Agerage resting HR on medical rate control arm = 77bpm.</li>
                    <li>Primary Endpoint = change in LVEF on repeat cardiac MRI at 6 months.</li>
                    
                </ul>
            </div>
        </div>
        
        <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
    </div>
    
    <!--results-->
    <div class="block" style="margin-top:10vh">
                      
        <div class="w3-row">
            
            <div class="w3-col w3-mobile s6" style="padding:0.5vmax">
                
            <ul class="san hoverBlue w3-ul" style="font-size:2.2vmax;line-height:130%;color: #969696">
                <span class="firstL sanB" style="line-height:150%">RESULTS</span>
                <li style="padding:1.5vmax">Catheter ablation (CA) significantly improved LVEF (18.3% increased) at 6 months
                    compared to medical rate control (MRC) group (4.4% increased).
                </li>
                <li style="padding:1.5vmax">
                    At 6 months, 58% of patients undergoing CA had normalized systolic function
                    (LVEF ≥50%) compared with 9% in the MRC group (p = 0.0002). 
                </li>
                <li style="padding:1.5vmax">LVESV, LA volume, and BNP level were significantly improved in the CA group.</li>
            </ul></div>
            <div class="w3-col s6 w3-mobile w3-padding">
                <img src="media/Camera/result.png" style="width:100%;padding:2vmax"></div>                            
                
            </div>
        <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
    </div>

    <!--subanalysis-->
    <div class="block" style="margin-top:10vh">
                      
        <div class="w3-row w3-center">
            <span class="firstL sanB" style="font-size: 3vmax">Sub-Group Analysis</span>
            <img src="media/Camera/LGE.png" style="width:90%"> 
        
            <ul class="san hoverBlue w3-ul" 
            style="font-size:2.2vmax;line-height:130%;color: #969696;text-align: left;padding: 0 2vmax">
               
                <li style="padding:1vmax">In those undergoing CA (n = 36), the LGE-negative group (n = 22) 
                    had a significantly greater improvement in absolute LVEF at 6 months compared with 
                    LGE-positive patients (n = 14) (11.6% vs. 22.3%; p = 0.0069).
                </li>
                <li style="padding:1vmax">
                    On multivariable analysis, only the absence of LGE predicted LVEF normalization (p = 0.0342)
                </li>
                
            </ul>
        </div>
        <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
    </div>

    <!--conclusion-->
    <div class="block san w3-center" style="margin-top:15vh; font-size: 2.8vmax;line-height: 130%;
        padding: 1vmax 6vmax;color:#0B3976">
        <span class="sanB w3-center" style="font-size:3vmax;color:#2E80EC">
        CONCLUSIONS: CAMERA-MRI
        </span><br><br>
        AF is an underappreciated reversible cause of LVSD in this population despite adequate rate control.<br>
        <br>
        The restoration of sinus rhythm with CA results in significant improvements in ventricular function, 
        particularly in the absence of ventricular fibrosis on CMR. 
        <div class="ref">
        <a href="https://www.sciencedirect.com/science/article/pii/S073510971739349X?via%3Dihub" target="_blank">
            CAMERA-MRI</a></div>
        <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
    </div>

</div>

<!--CASTLE-->
<div class="blockHolder gradient3" style="margin-top: 10vh">
    <!--intro-->    
    <div class="block" style="margin:0;padding: 0">
            <div class="eyebrow"></div>
            <div class="topic">
                <span>Trials ></span>
                <span>> CASTLE-AF</span>
                
            </div>
            <div class="ref" style="margin-left: 1.2vmax">
                    <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1707855" target="_blank">
                        ref: CASTLE-AF</a>
                </div>
    <!--intro-->
        <div class="w3-row w3-center" style="margin-top:7vh">
            <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1707855" target="_blank">
            <img src="media/CASTLE AF/castleAF logo.png" style="max-width: 90%;mix-blend-mode:hard-light"></a>
            <div class="serif" style="color:#969696;font-size:1.2vmax;text-align: center;padding: 0.5vmax">
                CATHETER ABLATION versus standard conventional treatment in patients with 
            LEFT VENTRICULAR DYSFUNCTION and AF.</div>
                <ul class="sanB w3-center hoverBlue w3-ul" 
                style="font-size:2.5vmax;color: #969696;margin-top:5vh">
                    
                    <li>RCT, MULTICENTER, OPEN-LABELLED.</li>
                    <li>Symptomatic AF, LVEF≤35%, NYHAII+, AAD: failed/side effects/unwilling, ICD/CRT-D with A lead.</li>
                    <li>Catheter Ablation for AF vs. Medical Therapy for AF (rate and/or rhythm).</li>
                    <li>Primary endpoint of death or worsening HF; mean F/U 37.8mo.</li>
                    
                </ul></div>
       
            <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
        </div>
    
    <!--Prim Endpoint-->
    <div class="block" style="margin-top:15vh">
        <div class="imgSec w3-row w3-center w3-border-bottom">
            <img src="media/CASTLE AF/castleAF AF 1endpoint.png" style="width:95%">
            </div>
            <div class="headline">
                Primary composite endpoint occured in significantly fewer
                patients in the ablation group than in the medical therapy group.
            </div>              
            <div class="text">
                    (51 patients [28.5%] vs. 82 patients [44.6%]; hazard ratio, 0.62; 
                    95% confidence interval [CI], 0.43 to 0.87; P=0.007.)
            </div>
            
        <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
    </div>
         
    <!--2 Endpoint-->
    <div class="block" style="margin-top:10vh">
        <div class="imgSec w3-row w3-center w3-border-bottom">
            <div class="w3-col s6 w3-padding">
            <img src="media/CASTLE AF/castleAF AF death.png" style="width:100%"></div>
            <div class="w3-col s6 w3-padding">
            <img src="media/CASTLE AF/castleAF AF burden.png" style="width:100%"></div>
        </div>
            <div class="headline">
            Fewer deaths and lower AF burden in catheter ablation group.
            </div>        
            <div class="text">LVEF improvement also occurred more in ablation group.<br>
            The median absolute increase in LVEF from baseline to the 60-month follow-up visit was 8.0% 
            (interquartile range, 2.2 to 19.1) in the ablation group and was 0.2% (−3.0 to 16.1) in the medical-therapy group (P=0.005). 
            </div>      
                        
        <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
    </div>

    <!--subanalysis-->
    <div class="block" style="margin-top:10vh">
            <div class="imgSec w3-row w3-center w3-border-bottom">
                <div class="w3-col s6 w3-padding">
                <img src="media/CASTLE AF/subgroup1.png" style="width:100%"></div>
                <div class="w3-col s6 w3-padding">
                <img src="media/CASTLE AF/subgroup2.png" style="width:100%"></div>
            </div>
                <div class="headline">
                Benefits were seen more in those with LVEF &ge;25%.
                </div>        
                  
                            
            <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
        </div>

    <!--conclusion-->
    <div class="block" style="margin-top:10vh">
            <div class="w3-row w3-center">
                <div class="w3-col s7 w3-padding w3-mobile">
                    <img src="media/CASTLE AF/table sum.jpeg" style="width:100%"></div>
                <div class="w3-col s5 san w3-padding w3-mobile" style="font-size:2vmax;text-align: left">
                    <div class="serif blueTxt" style="font-size:3vmax">Conclusions</div>
                    Catheter ablation for AF in patients with heart failure
                    was associated with a significantly
                     lower rate of a composite end point of
                     death from any cause or hospitalization
                     for worsening heart failure than was medical therapy.
                </div>
            <div class="ref w3-row w3-center">
                <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1707855" target="_blank">
                CASTLE-AF </a></div>
            </div>    
                
            </div>
            
                      
            <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
</div>
       


<!--commander-->
<div class="blockHolder gradient3" style="margin-top: 10vh">
    <!--intro-->    
    <div class="block" style="margin:0;padding: 0">
            <div class="eyebrow"></div>
            <div class="topic">
                <span>Trials ></span>
                <span>> COMMANDER HF</span>
                
            </div>
            <div class="ref" style="margin-left: 1.2vmax">
                    <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1808848" target="_blank">
                        ref: COMMANDER HF</a>
                </div>
    <!--intro-->
    <div class="w3-row w3-center" style="margin-top:7vh">
        <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1808848" target="_blank">
        <img src="media/Commander/frontpage.png" style="max-width: 90%;"></a>
        
        <ul class="sanB w3-center hoverBlue w3-ul" 
        style="font-size:2.5vmax;color: #969696;margin-top:5vh">
            
            <li>RCT, DOUBLE-BLINDED.</li>
            <li>5022 patients with HFrEF, CAD, without AF.</li>
            <li>Rivaroxaban 2.5 mg BID vs. placebo.</li>
            <li>Primary efficacy outcome: death, MI, or stroke.</li>
            <li>Primary safety outcome: fatal bleeding or bleeding into critical space.</li>
            
        </ul>
   
        <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
    </div>
    </div>

    <!--Prim Endpoint-->
    <div class="block" style="margin-top:15vh">
        <div class="imgSec w3-row w3-center w3-border-bottom">
            <img src="media/Commander/1endpoint.png" style="width:90%">
            </div>
            <div class="headline">
                No significant difference in primary efficacy endpoint was noted between 
                the rivaroxaban group and the placebo group.
            </div>              
            <div class="text">
                The primary efficacy outcome occurred in 626 patients (25.0%) assigned to rivaroxaban
                and 658 patients (26.2%) assigned to placebo (HR, 0.94; 95% CI, 0.84 to 1.05; P=0.27). <br>
                A total of 1284 events occurred which is enough to provide more than
                80% power to detect a 20% lower HR, with a 2-sided type I error of 0.05.
            </div>
            
        <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
    </div>

    <!--2 Endpoint-->
    <div class="block" style="margin-top:15vh">
            <div class="imgSec w3-row w3-center w3-border-bottom">
                <img src="media/Commander/all outcomes.png" style="width:90%">
                </div>
                <div class="headline">
                    Rivaroxaban reduced MI and stroke, but not all-cause mortality.
                </div>              
                <div class="text">
                    
                </div>
            <div class="ref w3-center">
                <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1808848" target="_blank">
                COMMANDER HF</a>
            </div>    
            <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
        </div>
    
    <!--conclusion-->
    <div class="block" style="margin-top:15vh">
            <div class="w3-container w3-center" style="width:70%;margin: auto">
            <i class="fas fa-quote-left" style="color:#e1ded7;font-size:8vmax;padding: 1vmax"></i><br>
            <span style="color:#0B3976;font-size: 3vmax" class="sanB" >
            ...the results of COMMANDER HF support the position that oral anticoagulation is not 
            indicated for patients with heart failure and reduced ejection fraction in the absence
             of atrial fibrillation.    
            </span>
            <div class="ref">
                <a href="https://www.nejm.org/doi/full/10.1056/NEJMe1811089?query=recirc_top_ribbon_article_4" target="_blank">
                    Pfeffer and Tardif. Editorial Section.</a>
            </div>
        
            </div>
            
                
            <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
        </div>
</div>

<!--APAF CRT-->
<div class="blockHolder gradient3" style="margin-top: 10vh">
        <!--intro-->    
        <div class="block" style="margin:0;padding: 0">
                <div class="eyebrow"></div>
                <div class="topic">
                    <span>Trials ></span>
                    <span>> APAF-CRT</span>
                    
                </div>
                <div class="ref" style="margin-left: 1.2vmax">
                        <a href="https://doi.org/10.1093/eurheartj/ehy555" target="_blank">
                            ref: APAF-CRT</a>
                    </div>
        <!--intro-->
        <div class="w3-row w3-center" style="margin-top:7vh">
            <a href="https://doi.org/10.1093/eurheartj/ehy555" target="_blank">
            <img src="media/APAF/frontpage.png" style="max-width: 90%;"></a>
            
            <ul class="sanB w3-center hoverBlue w3-ul" 
            style="font-size:2.5vmax;color: #969696;margin-top: 3vh">
                
                <li>RCT, N=102, mean age 72, f/u 16 months.</li>
                <li>Severely symptomatic permanent AF, QRS &le;110ms, and at least 1 hospitalization
                    for AF or HF in the previous year.</li>
                <li>AF: Permanent AF for > 6months; unsuitable for or failed catheter ablation.</li>
                <li>AV junction ablation + CRT vs. pharmacologic rate control.</li>
                <li>Primary composite outcome: death due to HF, or hospitalization due to HF, or worsening HF.</li>
                
            </ul>
       
            <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
        </div>
        </div>
    
        <!--Prim Endpoint-->
        <div class="block" style="margin-top:15vh">
            <div class="imgSec w3-row w3-center w3-border-bottom">
                <img src="media/APAF/APAF CRT.png" style="width:100%">
                </div>
                <div class="headline">
                    In comparison with control arm, AV junction ablation + CRT reduced 
                    the risks of primary endpoint by 62%. 
                </div>              
                <div class="text">
                        Ablation+CRT patients also showed a 36% decrease in the specific
                        symptoms and physical limitations of AF at 1 year follow-up (P = 0.004).   
                </div>
                
            <div class="w3-btn next" style="left: 90vw" onmouseover="blockNav(1)"></div>
        </div>
            
    </div>

<!--end pointer-->
</div>


<script src="block navigation.js" ></script>
<script>

window.addEventListener("keydown", function(event) {
        event.preventDefault();
        if (event.keyCode===32) {
        var p = document.getElementsByClassName("pointer");
        p[0].style.display = "none";}
    })

//up arrow
window.addEventListener("keydown", function(event) {
    event.preventDefault();
    if (event.keyCode===38) {
    blockNav(-1)}
})
//down arrow
window.addEventListener("keydown", function(event) {
    event.preventDefault();
    if (event.keyCode===40) {
    blockNav(1)}
})

window.addEventListener("keydown", function(event) {
        event.preventDefault();
        if (event.keyCode===27) {
        window.unblur()}
    })

window.onload = function () {unblur()};
window.ontouchmove = function () {unblur()};
window.onscroll = function () {scroll()};


function pointer() {
    var x = event.clientX;
    var y = event.clientY;
    var p = document.getElementsByClassName("pointer");
    p[0].style.display = "inline";
    p[0].style.left = x+"px"; 
    p[0].style.top = y+"px";
    }

//show menu

function showMenu() {
    unblur();
    var icon = document.getElementsByClassName('menuIcon');
    icon[0].style.display="none";
    var hide = document.getElementsByClassName('hideItem');
    hide[0].style.display="block";
}

function hideMenu() {
    var icon = document.getElementsByClassName('menuIcon');
    var hide = document.getElementsByClassName('hideItem');
    hide[0].style.display="none";
    icon[0].style.display="block";
}

function scroll() {
    menu = document.getElementsByClassName("menu");
    hideMenu();   
    if (window.pageYOffset>=window.innerHeight){
        menu[0].style.display="block"}
    else {
        menu[0].style.display="none"}
}

</script>	

</body>
</html>
